The Beauty Health Company (NASDAQ: SKIN), a global category-creator in beauty health leading the charge with its flagship brand HydraFacialTM, today announced that, following its third quarter record performance, Clint Carnell will be transitioning out of his role as Chief Executive Officer of the Company. Mr. Carnell will also be stepping down from the Board of Directors (the “Board”) of the Company. By mutual agreement with the Board, Mr. Carnell will serve as CEO and as a director through December 31, 2021. Effective January 1, 2022, Brent Saunders, Executive Chairman of the Board of BeautyHealth, will assume additional responsibilities of the CEO until a permanent successor is named.

These actions are not related to any matter regarding the Company's financial condition, reported financial results, internal controls or disclosure controls and procedures. Mr. Saunders is expected to serve as the CEO until a permanent successor is identified and will remain Chair of the Board of Directors.

“We are excited for the future of the Company as we execute on our next phase of growth, which will focus on deepening brand awareness, further increasing innovation, and expanding our international footprint,” said Mr. Saunders. “We delivered a record third quarter performance, which speaks to the underlying strength of the business. We are building an enduring and premier company in the category of beauty health.”

Mr. Saunders continued, “We thank Clint for his efforts over the past five years, particularly as he guided the business through the COVID-19 pandemic and led the Company through the business combination earlier this year. He helped create a strong platform as we continue to grow, both organically and through select acquisitions. BeautyHealth is the clear leader in a category we created.”

Mr. Carnell said, “It has been my honor to be part of building this category creating brand, and I am proud of what we have accomplished over the past five years. BeautyHealth is positioned stronger than ever to succeed, as we continue to execute across key strategic initiatives. While the Board conducts its search for a new permanent CEO, I look forward to working with our talented management team to ensure a seamless transition.”

About Brent Saunders

Brent Saunders has served as Executive Chairman of The Beauty Health Company since its inception in May 2021. He has over 25 years of experience in various aspects of healthcare and has been in leadership roles at several prominent global pharmaceutical and healthcare companies. Until May 2020, when it was acquired by AbbVie Inc. in a transaction valued at approximately $84 billion, Mr. Saunders served as Chairman, President and Chief Executive Officer of Allergan plc. His role as President and Chief Executive Officer of Allergan began in July 2014, and his added role of Chairman began in October 2016. Mr. Saunders’ first role as an executive officer in the pharmaceuticals and healthcare sectors began in 2003, as a member of the executive management team at Schering-Plough Corporation, where he held several key roles, including President of the company’s Global Consumer Health Care division. While at Schering-Plough, Mr. Saunders led the integrations of the company’s $14 billion acquisition of Organon Biosciences N.V in 2007 as well as the merger between Schering-Plough and Merck & Co., Inc. in 2009. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, a leading global eye health company, until its acquisition by Valeant Pharmaceuticals, Inc. in 2013. He then became the Chief Executive Officer of Forest Laboratories Inc., a role he held until the company’s merger with Actavis plc in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business. In 2015, he led Actavis’ acquisition of Allergan, renaming the combined company Allergan Plc. ​Before joining Schering-Plough in 2003, Mr. Saunders was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was Chief Risk Officer at Coventry Health Care, Inc. and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System.​

Mr. Saunders currently serves as a director of Cisco Systems, Inc., a global telecommunications company and BridgeBio Pharma Inc., a bio pharmaceutical company. He is also a member of The Business Council.